Damora Therapeutics Rises as Traders Focus on Near-Term Pipeline Catalysts

Damora Therapeutics (DMRA) is up 12.4% today. Here is some analysis on what might have caused this price movement.

Analysis: No obvious same-day company announcement appears to explain the jump, so the move looks most likely tied to renewed interest in Damora’s upcoming regulatory milestones and its preclinical blood-disorder pipeline. This could be because investors are positioning ahead of the company’s expected mid-2026 submission for lead program DMR-001, while its large cash balance gives it room to advance development.

Details:

Damora said in its first-quarter update that DMR-001, its lead mutant calreticulin-targeted antibody program, remains on track for a first regulatory submission in mid-2026, with DMR-002 targeted for the second half of 2026.

The same corporate update highlighted preclinical data for DMR-001 that the company said showed strong potency, half-life and anti-mutCALR activity, supporting the program’s positioning as a differentiated asset.

Damora had about $532.9 million in cash and cash equivalents as of March 31, 2026, and said that cash runway is expected to fund operations into 2029.

A June 17 annual-meeting filing showed routine shareholder approvals rather than a major new corporate event, which suggests today’s gain may reflect momentum trading or speculation around pending pipeline milestones instead of a fresh filing-driven catalyst.

Sources:

Damora Therapeutics Investor Relations, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DMRA Hedge Fund Activity

We have seen 53 institutional investors add shares of $DMRA stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 8,806,603 shares (+3686.7%) to their portfolio in Q1 2026, for an estimated $228,091,017
FAIRMOUNT FUNDS MANAGEMENT LLC added 8,713,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $225,666,700
AVORO CAPITAL ADVISORS LLC added 3,783,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $97,979,700
FCPM III SERVICES B.V. added 2,441,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $63,221,900
RA CAPITAL MANAGEMENT, L.P. added 2,399,310 shares (+inf%) to their portfolio in Q1 2026, for an estimated $62,142,129
VIKING GLOBAL INVESTORS LP added 2,311,082 shares (+inf%) to their portfolio in Q1 2026, for an estimated $59,857,023
BELLEVUE GROUP AG added 2,298,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $59,518,200

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DMRA Price Targets

Multiple analysts have issued price targets for $DMRA recently. We have seen 4 analysts offer price targets for $DMRA in the last 6 months, with a median target of $42.5.

Here are some recent targets:

David Nierengarten from Wedbush set a target price of $35.0 on 06/12/2026
Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $45.0 on 06/11/2026
Brian Abrahams from RBC Capital set a target price of $40.0 on 04/24/2026
Gavin Clark-Gartner from Evercore ISI Group set a target price of $46.0 on 03/25/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.